Application of mechanism-based CYP inhibition for predicting drug-drug interactions

Expert Opinion on Drug Metabolism and Toxicology

Volumn 5, Issue 6, 2009, Pages 579-605

  Zhou, Zhi Wei ^a   Zhou, Shu Feng ^a  

^a RMIT UNIVERSITY   (Australia)

Author keywords

CYP; Drug interaction; Mechanism based inhibition

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; AMIODARONE; AMITRIPTYLINE; AMLODIPINE; AMPRENAVIR; ATAZANAVIR; AZITHROMYCIN; BERGAMOTTIN; BROMOCRIPTINE; BUPRENORPHINE; CIMETIDINE; CLARITHROMYCIN; CLOPIDOGREL; CLOZAPINE; CYCLOSPORIN; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 3A4; DASATINIB; DELAVIRDINE; DESIPRAMINE; DICLOFENAC; DIHYDRALAZINE; DILTIAZEM; DPC 681; ERYTHROMYCIN; ETHINYLESTRADIOL; L 754394; N NORDILTIAZEM; PROADIFEN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SUICIDE SUBSTRATE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CONCENTRATION RESPONSE; DRUG ELIMINATION; ENZYME DEGRADATION; ENZYME INACTIVATION; ENZYME INHIBITION; FIRST PASS EFFECT; HUMAN; PREDICTION; REVIEW; TIME;

ALGORITHMS; ANIMALS; AREA UNDER CURVE; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ENZYME INHIBITORS; HUMANS; PHARMACEUTICAL PREPARATIONS;

EID: 67649382514     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425250902926099     Document Type: Review

References (100)

1. Krayenbuhl JC, Vozeh S, Kondo-Oestreicher M, et al. Drug-drug interactions of new active substances: mibefradil example. Eur J Clin Pharmacol 1999;55:559-565 • An excellent paper to address the importance of drug-drug interaction studies in drug development using mibefradil as an example. (Pubitemid 29489201)
2. Li AP. Screening for human ADME/Tox drug properties in drug discovery. Drug Discov Today 2001;6:357-366 • An excellent review highlights current screening approaches for examining drug MADE/TOx properties. (Pubitemid 32208650)
3. Zhou SF, Xue CC, Yu XQ, et al. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit 2007;29:687-710 • An excellent review on clinical drug-drug interactions caused by mechanism-based CYP3A4 inhibition. (Pubitemid 350190847)
4. Available from: http://drnelson.utmem.edu/CytochromeP450.html, [Access date: 26 March 2009]
5. Nebert DW, Russell DW. Clinical importance of the cytochromes P450. Lancet 2002;360:1155-1162 • An excellent review on the clinical relevance of CYP enzymes. (Pubitemid 35246494)
6. Zhou SF. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab 2008;9:310-322 • An excellent paper updating our knowledge on drugs that interact with CYP3A4.
7. Shimada T, Yamazaki H, Mimura M, et al. Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals. J Pharmacol Exp Ther 1994;270:414-423 • A classical paper with important data on contents of various hepatic CYPs in humans; but recent data have revealed slightly different values of these CYPs.
8. Zhou SF, Di YM, Chan E, et al. Clinical pharmacogenetics and potential application in personalized medicine. Curr Drug Metab 2008;9:738-784 • An excellent paper to summarize the potential role of pharmacogenetic testing and limitations in personalized medicine.
9. Zhou S, Chan E, Lim LY, et al. Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4. Curr Drug Metab 2004;5:415-442 • A comprehensive review to discuss individual drugs that are reported to be mechanism-based inhibitors of CYP3A4 and the clinical and toxicological relevance. (Pubitemid 39276605)
10. Houston JB, Galetin A. Methods for predicting in vivo pharmacokinetics using data from in vitro assays. Curr Drug Metab 2008;9:940-51 •• An excellent review on the predicting approaches for in vivo pharmacokinetic parameters based on in vitro data.
11. Obach RS, Walsky RL, Venkatakrishnan K. Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions. Drug Metab Dispos 2007;35:246-55 •• An excellent paper to address on how to conduct in vitro-in vivo extrapolation when mechanism-based inhibition of CYP occurs using eight marker reactions in pooled human liver microsomes.
12. Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000;38:41-57 •• An excellent review summarizing current knowledge about the clinical outcomes of CYP3A4 inhibition. (Pubitemid 30055093)
13. Riley RJ, Grime K, Weaver R. Time-dependent CYP inhibition. Expert Opin Drug Metab Toxicol 2007;3:51-66 • An excellent mini-review highlights the concept of time-dependent enzyme inhibition. (Pubitemid 47315418)
14. Spinler SA, Cheng JW, Kindwall KE, et al. Possible inhibition of hepatic metabolism of quinidine by erythromycin. Clin Pharmacol Ther 1995;57:89-94
15. Michalets EL, Williams CR. Drug interactions with cisapride: clinical implications. Clin Pharmacokinet 2000;39:49-75 (Pubitemid 30468204)
16. Jurima-Romet M, Crawford K, Cyr T, et al. Terfenadine metabolism in human liver. In vitro inhibition by macrolide antibiotics and azole antifungals. Drug Metab Dispos 1994;22:849-857
17. Honig PK, Wortham DC, Zamani K, et al. Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences. JAMA 1993;269:1513-1518 • First report on dangerous terfenadine-ketoconazole interaction in humans. (Pubitemid 23086411)
18. Honig PK, Woosley RL, Zamani K, et al. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther 1992;52:231-238 • First report on dangerous terfenadine-erythomycin interaction in humans.
19. Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 2002;41:343-370 • An excellent paper summarizing the clinical statin-drug interactions. (Pubitemid 34713089)
20. Anderson JR, Nawarskas JJ. Cardiovascular drug-drug interactions. Cardiol Clin 2001;19:215-234
21. Simonsen U. Interactions between drugs for erectile dysfunction and drugs for cardiovascular disease. Int J Impot Res 2002;14:178-188 (Pubitemid 34760547)
22. Spina E, Pisani F, Perucca E. Clinically significant pharmacokinetic drug interactions with carbamazepine. An update. Clin Pharmacokinet 1996;31:198-214 • A good paper summarizing drug interactions with carbamazepine. (Pubitemid 26335906)
23. Rathbun RC, Rossi DR. Low-dose ritonavir for protease inhibitor pharmacokinetic enhancement. Ann Pharmacother 2002;36:702-706 (Pubitemid 34270289)
24. Kempf DJ, Marsh KC, Kumar G, et al. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother 1997;41:654-660 (Pubitemid 27098420)
25. Liebler DC, Guengerich FP. Elucidating mechanisms of drug-induced toxicity. Nat Rev Drug Discov 2005;4:410-420 •• An excellent paper discussing the potential mechanisms for predictable and unpredictable adverse drug reactions. (Pubitemid 40704124)
26. Chitturi S, George J. Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs. Semin Liver Dis 2002;22:169-183 (Pubitemid 34496470)
27. Tornqvist M, Fred C, Haglund J, et al. Protein adducts: quantitative and qualitative aspects of their formation, analysis and applications. J Chromatogr B Analyt Technol Biomed Life Sci 2002;778:279-308
28. Cohen SD, Pumford NR, Khairallah EA, et al. Selective protein covalent binding and target organ toxicity. Toxicol Appl Pharmacol 1997;143:1-12 (Pubitemid 27130601)
29. Lin JH, Lu AYH. Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 1998;35:361-390 •• An excellent paper discussing the clinical significance of CYP induction and inhibition. (Pubitemid 28520008)
30. Fontana E, Dansette PM, Poli SM. Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity. Curr Drug Metab 2005;6:413-454 • A good paper investigating the physicochemical properties of drugs causing mechanism-based CYP inhibition. (Pubitemid 41300789)
31. Zhou S, Yung Chan S, Cher Goh B, et al. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet 2005;44:279-304 • A good review highlights the clinical relevance of mechanism-based CYP inhibition by drugs. (Pubitemid 40477790)
32. Voorman RL, Maio SM, Hauer MJ, et al. Metabolism of delavirdine, a human immunodeficiency virus type-1 reverse transcriptase inhibitor, by microsomal cytochrome P450 in humans, rats, and other species: probable involvement of CYP2D6 and CYP3A. Drug Metab Dispos 1998;26:631-639 (Pubitemid 28345846)
33. Schrag ML, Wienkers LC. Covalent alteration of the CYP3A4 active site: evidence for multiple substrate binding domains. Arch Biochem Biophys 2001;391:49-55 (Pubitemid 32612572)
34. Franklin MR. Cytochrome P450 metabolic intermediate complexes from macrolide antibiotics and related compounds. Methods Enzymol 1991;206:559-573 • First report on metabolic intermediate formation with CYP3A and macrolides.
35. Lillibridge JH, Liang BH, Kerr BM, et al. Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate. Drug Metab Dispos 1998;26:609-616 (Pubitemid 28345843)
36. Venkatakrishnan K, Obach RS, Rostami-Hodjegan A. Mechanism-based inactivation of human cytochrome P450 enzymes: strategies for diagnosis and drug-drug interaction risk assessment. Xenobiotica 2007;37:1225-1256 •• An excellent paper to discuss the risk evaluation of drug-drug interactions involving mechanism-based CYP inhibition. (Pubitemid 350035532)
37. Venkatakrishnan K, Obach RS. Drug-drug interactions via mechanism-based cytochrome P450 inactivation: points to consider for risk assessment from in vitro data and clinical pharmacologic evaluation. Curr Drug Metab 2007;8:449-62 •• An excellent review paper on the prediction of drug-drug interactions due to mechanism-based CYP inhibition based on in vitro data and clinical pharmacokinetic studies. (Pubitemid 47603409)
38. Kalgutkar AS, Obach RS, Maurer TS. Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions. Curr Drug Metab 2007;8:407-447 •• An excellent and comprehensive paper summarizing our current knowledge on drug-drug interactions due to mechanism-based CYP inhibition and potential clinical and toxicological relevance. (Pubitemid 47603408)
39. Ghanbari F, Rowland-Yeo K, Bloomer JC, et al. A critical evaluation of the experimental design of studies of mechanism based enzyme inhibition, with implications for in vitro-in vivo extrapolation. Curr Drug Metab 2006;7:315-34 •• An excellent paper reviewing the experimental design of mechanism-based CYP inhibition studies and methodology consideration for in vitro-in vivo extrapolation.
40. Silverman RB. Mechanism-based enzyme inactivation: chemistry and enzymology. Boca Raton, FL: CRC Press; 1998 •• An excellent book discussing mechanism-based enzyme inhibition with regard to biochemical mechanisms involved and enzyme kinetics in details.
41. Wilson RC, Kitzman JV, Kemp DT, et al. Compartmental and noncompartmental pharmacokinetic analyses of minocycline hydrochloride in the dog. Am J Vet Res 1985;46:1316-1318 (Pubitemid 15086445)
42. Tudela J, Garcia Canovas F, Varon R, et al. Transient-phase kinetics of enzyme inactivation induced by suicide substrates. Biochim Biophys Acta 1987;912:408-416 (Pubitemid 17066100)
43. Mayhew BS, Jones DR, Hall SD. An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metab Dispos 2000;28:1031-7 •• An excellent paper to predict in vivo CYP3A4 inactivation using in vitro data.
44. Obach RS, Walsky RL, Venkatakrishnan K, et al. The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther 2006;316:336-348 •• An excellent paper examining the potential for predicting in vivo drug-drug interactions based on in vitro data. (Pubitemid 41832613)
45. Fairman DA, Collins C, Chapple S. Progress curve analysis of CYP1A2 inhibition: a more informative approach to the assessment of mechanism-based inactivation? Drug Metab Dispos 2007;35:2159-2165 • An interesting paper that reported a new method to evaluate kinetic parameters for mechanism-based enzyme inhibition.
46. Dash C, Phadtare S, Deshpande V, et al. Structural and mechanistic insight into the inhibition of aspartic proteases by a slow-tight binding inhibitor from an extremophilic Bacillus sp.: correlation of the kinetic parameters with the inhibitor induced conformational changes. Biochemistry 2001;40:11525-11532
47. Austin RP, Barton P, Cockroft SL, et al. The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties. Drug Metab Dispos 2002;30:1497-503 • A good paper highlights the importance of correction for non-specific microsomal binding for the estimation of enzyme kinetic parameters and in vivo prediction.
48. Wienkers LC, Heath TG. Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov 2005;4:825-833 •• A perfect paper summarizing our current knowledge and progress on predicting in vivo drug-drug interactions based on data from in vitro studies. (Pubitemid 41553963)
49. Ito K, Iwatsubo T, Kanamitsu S, et al. Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol Rev 1998;50:387-411 •• A very useful review addressing the prediction of metabolic drug-drug interactions and the uncertainty sources for the prediction in details. (Pubitemid 28477680)
50. Youdim KA, Zayed A, Dickins M, et al. Application of CYP3A4 in vitro data to predict clinical drug-drug interactions; predictions of compounds as objects of interaction. Br J Clin Pharmacol 2008;65:680-692 • An excellent paper reporting the prediction of drug-drug interactions involving CYP3A4 inhibition.
51. Brown HS, Galetin A, Hallifax D, et al. Prediction of in vivo drug-drug interactions from in vitro data: factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4. Clin Pharmacokinet 2006;45:1035-50 •• An excellent paper discussing the prediction of drug-drug interactions based on in vitro data.
52. Waley SG. Kinetics of suicide substrates. Practical procedures for determining parameters. Biochem J 1985;227:843-849
53. Correia MA. Cytochrome P450 turnover. Methods Enzymol 1991;206:315-325
54. Wilkinson GR, Shand DG. Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther 1975;18:377-390
55. Houston JB. Drug metabolite kinetics. Pharmacol Ther 1982;15:521-552 (Pubitemid 12054891)
56. Ito K, Hallifax D, Obach RS, et al. Impact of parallel pathways of drug elimination and multiple cytochrome P450 involvement on drug-drug interactions: CYP2D6 paradigm. Drug Metab Dispos 2005;33:837-844 • A good example showing the incorporation of multiple metabolic pathways and multiple enzymes involvement in predicting drug-drug interactions. (Pubitemid 40686638)
57. Kanamitsu S, Ito K, Green CE, et al. Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4. Pharm Res 2000;17:419-426 (Pubitemid 30395296)
58. Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res 1993;10:1093-1095 • An excellent paper listing the values of a number of important physiological parameters. (Pubitemid 23211439)
59. Rostami-Hodjegan A, Tucker GT. 'In silico' simulations to assess the 'in vivo' consequences of 'in vitro' metabolic drug-drug interactions. Drug Discov Today Tech 2004;1:441-448
60. Galetin A, Burt H, Gibbons L, et al. Prediction of time-dependent CYP3A4 drug-drug interactions: impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition. Drug Metab Dispos 2006;34:166-175 •• An excellent paper highlighting the importance of accurate estimation of CYP degradation, parallel elimination routes and inhibition of intestinal first-pass metabolism in the prediction of drug-drug interactions due to CYP inactivation. (Pubitemid 43042658)
61. Thummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 1998;38:389-430 •• An excellent review summarizing drug interactions involving CYP3A.
62. Yang J, Jamei M, Yeo KR, et al. Theoretical assessment of a new experimental protocol for determining kinetic values describing mechanism (time)-based enzyme inhibition. Eur J Pharm Sci 2007;31:232-241 • An excellent paper evaluating a new experimental design for determining kinetic parameters in mechanism-based CYP inhibition. (Pubitemid 46818983)
63. Grime KH, Bird J, Ferguson D, et al. Mechanism-based inhibition of cytochrome P450 enzymes: an evaluation of early decision making in vitro approaches and drug-drug interaction prediction methods. Eur J Pharm Sci 2009;36:175-91 •• An excellent paper highlights the potential for determining kinact/KI ratios using two different methods and extrapolation to in vivo situations.
64. Rodrigues AD, Wong SL. Application of human liver microsomes in metabolism-based drug-drug interactions: in vitro-in vivo correlations and the Abbott Laboratories experience. Adv Pharmacol 1997;43:65-101
65. Azie NE, Brater DC, Becker PA, et al. The interaction of diltiazem with lovastatin and pravastatin. Clin Pharmacol Ther 1998;64:369-377 (Pubitemid 28473762)
66. Backman JT, Olkkola KT, Aranko K, et al. Dose of midazolam should be reduced during diltiazem and verapamil treatments. Br J Clin Pharmacol 1994;37:221-225 (Pubitemid 24212179)
67. Laganière S, Davies RF, Carignan G, et al. Pharmacokinetic and pharmacodynamic interactions between diltiazem and quinidine. Clin Pharmacol Ther 1996;60:255-264 (Pubitemid 26354446)
68. Gorski JC, Jones DR, Haehnerdaniels BD, et al. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin Pharmacol Ther 1998;64:133-143 • A paper highlighting the importance for the incorporation of intestinal metabolism of drugs in drug-drug interaction prediction. (Pubitemid 28423848)
69. Greenblatt DJ, Preskorn SH, Cotreau MM, et al. Fluoxetine impairs clearance of alprazolam but not of clonazepam. Clin Pharmacol Ther 1992;52:479-486
70. Chien JY, Thummel KE, Slattery JT. Pharmacokinetic consequences of induction of CYP2E1 by ligand stabilization. Drug Metab Dispos 1997;25:1165-1175 (Pubitemid 27446587)
71. Wang YH, Jones DR, Hall SD. Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos 2004;32:259-66 •• An excellent paper reporting the prediction of in vivo drug-verapamil interactions involving CYP3A inactivation.
72. Lamberg TS, Kivisto KT, Neuvonen PJ. Effects of verapamil and diltiazem on the pharmacokinetics and pharmacodynamics of buspirone. Clin Pharmacol Ther 1998;63:640-645 (Pubitemid 28327891)
73. Kantola T, Kivisto KT, Neuvonen PJ. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 1998;64:177-182 (Pubitemid 28423853)
74. Lampen A, Christians U, Guengerich FP, et al. Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability. Drug Metab Dispos 1995;23:1315-1324 (Pubitemid 26007838)
75. Ma B, Prueksaritanont T, Lin JH. Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos 2000;28:125-130 (Pubitemid 30068994)
76. Schuetz EG, Beck WT, Schuetz JD. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol 1996;49:311-318 (Pubitemid 26066117)
77. Venkatakrishnan K, Obach RS. In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude. Drug Metab Dispos 2005;33:845-852 •• An excellent example showing the impact of fm(CYP2D6) and [I] on the prediction precision using paroxetine as a model inactivator of CYP2D6.
78. Lu P, Schrag ML, Slaughter DE, et al. Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. Drug Metab Dispos 2003;31:1352-60 • A report showing the in vitro estimation of enzyme kinetic parameters for mechanism-based inhibition of CYP1A2 by zileuton.
79. Karjalainen MJ, Neuvonen PJ, Backman JT. Rofecoxib is a potent, metabolism-dependent inhibitor of CYP1A2: implications for in vitro prediction of drug interactions. Drug Metab Dispos 2006;34:2091-2096 (Pubitemid 44841888)
80. Backman JT, Karjalainen MJ, Neuvonen M, et al. Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjects. Br J Clin Pharmacol 2006;62:345-357 • An excellent clinical report showing the interaction of tizanidine and caffeine with rofecoxib, a mechanism-based CYP1A2 inactivator. (Pubitemid 44215535)
81. Bachmann K, White D, Jauregui L, et al. An evaluation of the dose-dependent inhibition of CYP1A2 by rofecoxib using theophylline as a CYP1A2 probe. J Clin Pharmacol 2003;43:1082-1090 • Another excellent clinical report showing the interaction of theophylline with rofecoxib, a mechanism-based CYP1A2 inactivator. (Pubitemid 37174439)
82. Heydari A, Yeo KR, Lennard MS, et al. Mechanism-based inactivation of CYP2D6 by methylenedioxymethamphetamine. Drug Metab Dispos 2004;32:1213-7 • A short report on the inactivation of CYP2D6 by MDMA in vitro.
83. O'Mathuna B, Farre M, Rostami-Hodjegan A, et al. The consequences of 3, 4-methylenedioxymethamphetamine induced CYP2D6 inhibition in humans. J Clin Psychopharmacol 2008;28:523-9 •• An important in vivo human study showing direct evidence that MDMA inactivates CYP2D6.
84. Yang J, Jamei M, Heydari A, et al. Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA. J Psychopharmacol 2006;20:842-849 (Pubitemid 44622750)
85. Fahmi OA, Maurer TS, Kish M, et al. A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro. Drug Metab Dispos 2008;36:1698-1708 •• An interesting paper on the use of integrated model to predict clinical net drug-drug interactions due to CYP3A4 inhibition and induction.
86. Tucker GT, Houston JB, Huang SM. Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential - Towards a consensus. Br J Clin Pharmacol 2001;52:107-117 •• An excellent paper discussing the importance of evaluating drug-drug interactions in drug development. (Pubitemid 32862777)
87. Bjornsson TD, Callaghan JT, Einolf HJ, et al. The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 2003;31:815-832 (Pubitemid 36759050)
88. Liston HL, DeVane CL, Boulton DW, et al. Differential time course of cytochrome P450 2D6 enzyme inhibition by fluoxetine, sertraline, and paroxetine in healthy volunteers. J Clin Psychopharmacol 2002;22:169-73 •• An excellent report showing the time-dependent inhibition of CYP2D6 by several selective serotonin reuptake inhibitors in vivo.
89. Tornio A, Niemi M, Neuvonen M, et al. The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo. Clin Pharmacol Ther 2008;84:403-11 • Another report showing evidence that CYP2C8 is inhibited in a time-dependent manner in vivo.
90. Orlando R, De Martin S, Pegoraro P, et al. Irreversible CYP3A inhibition accompanied by plasma protein-binding displacement: a comparative analysis in subjects with normal and impaired liver function. Clin Pharmacol Ther 2009;85:319-26 • First paper to investigate the impact of liver function on quinine-erythromycin interaction in vivo.
91. Tonn GR, Wong SG, Wong SC, et al. An inhibitory metabolite leads to dose- and time-dependent pharmacokinetics of (R)-N-{1-[3-(4-ethoxy-phenyl)-4-oxo-3,4- dihydro-pyrido[2,3-d]pyrimidin-2-y l]-ethyl}-N-pyridin-3-yl-methyl-2-(4- trifluoromethoxy-phenyl)-acetamide (AMG 487) in human subjects after multiple dosing. Drug Metab Dispos 2009;37:502-13 • A recent report showing evidence for in vivo mechanism-based CYP inhibition in humans.
92. Tsao S-C, Dickinson TH, Abernethy DR. Metabolite inhibition of parent drug biotransformation. Studies of diltiazem. Drug Metab Dispos 1990;18:180-182
93. Bartkowski RR, Goldberg ME, Larijani GE, et al. Inhibition of alfentanil metabolism by erythromycin. Clin Pharmacol Ther 1989;46:99-102 (Pubitemid 19195780)
94. Mullins ME, Horowitz Z, Linden DHJ, et al. Life-threatening interaction of mibefradil and beta-blockers with dihydropyridine calcium channel blockers. JAMA 1998;280:157-158 • First report on life-threatening interaction of mibefradil (withdrawn in 1998) and β-blockers with dihydropyridine calcium channel inhibitors in patients. (Pubitemid 28498388)
95. Prueksaritanont T, Ma B, Tang C, et al. Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in vitro investigation with human liver preparations. Br J Clin Pharmacol 1999;47:291-298 (Pubitemid 29131344)
96. Zhou SF. Potential strategies for minimizing mechanism-based inhibition of cytochrome P450 3A4. Curr Pharm Des 2008;14:990-1000 •• An excellent paper discussing the potential for reducing the impact of mechanism-based CYP inhibition in drug development.
97. Tang W, Stearns RA, Wang RW, et al. Assessing and minimizing time-dependent inhibition of cytochrome P450 3A in drug discovery: a case study with melanocortin-4 receptor agonists. Xenobiotica 2008;38:1437-1451 • This paper reported the incorporation of minimizing mechanism-based CYP3A inhibition by new drug candidates in drug development of novel melanocortin-4 receptor agonists.
98. Jones DR, Ekins S, Li L, et al. Computational approaches that predict metabolic intermediate complex formation with CYP3A4 (+b5). Drug Metab Dispos 2007;35:1466-75 • An excellent paper reporting the use of in silico approaches to predict potential for metabolic intermediate complex formation with CYP3A4.
99. Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance. Drug Metab Rev 2009 (accepted) •• An excellent paper summarizing our knowledge on the genetic polymorphisms of CYP2D6 and the clinical impact.
100. Yang J, Liao M, Shou M, et al. Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions. Curr Drug Metab 2008;9:384-394 •• An excellent paper highlights the importance of accurate estimation of CYP turnover half-lives in the prediction for drug-drug interactions due to mechanism-based CYP inhibition. (Pubitemid 352025193)